Answers are grounded in this paper and cite their sources.
Flunarizine is used for migraine prevention in children and adolescents, yet its pharmacological basis in children remains poorly defined. We systematically searched PubMed, Embase, Scopus, and reference lists for original pharmacological studies relevant to migraine and clinical studies involving patients aged 18 years or younger. Findings were synthesized narratively, prioritizing pharmacology. Of 2019 identified records, 62 reports were included (47 pharmacological and 15 pediatric clinical reports) comprising four randomized trials and 11 nonrandomized studies. Very few studies were conducted to explore the pharmacological proprieties of flunarizine in children and adolescents, with none dedicated to migraine. Experimental studies demonstrate preparation-dependent inhibition of neuronal calcium and sodium currents, attenuation of changes associated with cortical spreading depolarization, and suppression of trigeminocervical neuronal responses. Dopaminergic and histaminergic interactions may contribute to adverse effects, but target engagement at pediatric preventive doses remains unknown. Small placebo-controlled trials suggest reduced migraine attack frequency whereas active-comparator trials and observational studies do not establish comparative superiority. Somnolence, weight gain, and mood changes are the principal reported tolerability concerns, while long-term safety remains insufficiently characterized. Flunarizine has a plausible multimodal rationale for migraine prevention in children and adolescents, but pediatric pharmacokinetic and exposure-response studies are needed to connect experimental findings with clinical benefit and risk.
No takes yet. Share an insight, caveat, or question.
Iannone et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: